FASN and metabolic dysfunction-associated steatohepatitis: However, this phenomenon was observed in the plasma from NASH patients treated with FASN inhibitor for 12 weeks, mouse models of both genetically or pharmacologically reduced DNL, and in cell culture models for mechanistical studies.